Valneva SE
INRLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$639.11M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $639.11 Million |
|---|---|
| Enterprise Value | $728.26 Million |
| Earnings per Share | $-0.68 |
| Beta | 1.35 |
| Outstanding Shares | 189,646,915 |
Return
| Return on Equity | -195.06% |
|---|---|
| Return on Assets | -40.75% |
| Return on Invested Capital | -41.44% |
Valuation & Multiples
| P/E Ratio | -2.58 |
|---|---|
| PEG | -1.49 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.07 |
| Enterprise Value to EBIT | -6.17 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 2.6 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.10
Consensus analyst estimateRevenue Estimate
$47.47 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.10
Consensus analyst estimateRevenue Estimate
$43.42 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Valneva SE
674 employees
CEO: Thomas Lingelbach
Founded in Saint-Herblain, France, in 1998, Valneva SE operates as a specialized biotechnology firm, concentrating on the creation and global distribution of preventative vaccines. Its primary focus is on infectious diseases for which cu...